BRCA2 and ovarian cancer: To determine the performance of the BARD1 OC test in women with mutations in BRCA1, BRCA2, or BARD1, or other predisposition genes, a pilot study was performed using the 20-peptide BARD1 panel for ELISA tests for measuring BARD1 autoimmune antibodies and CA125 in 261 plasma samples including samples from ovarian cancer patients with or without mutations in BRCA1/2 or other predisposition genes and healthy controls.